Instrument Inactif

Communiqués Wntresearch AB Nasdaq Stockholm

Actions

Cours en clôture Nasdaq Stockholm
- ^SEK	-

07/04/25	Wntresearch est cotée aujourd'hui sur Spotlight sous son nouveau nom Opsy.	FW
04/04/25	Opsy change les dates de son assemblée générale annuelle et de son rapport trimestriel	FW

Communiqués

04/02/25	BioStock: WntResearch CEO comments on reverse acquisition	AQ
17/10/24	BioStock: WntResearch updates after stopped study	AQ
09/10/24	WntResearch: WntResearch provides an update on the work in progress to safeguard the interests of shareholders and company values	PU
09/10/24	WntResearch provides an update on the work in progress to safeguard the interests of shareholders and company values	AQ
20/09/24	BioStock: WntResearch plummets after results	AQ
27/08/24	WntResearch's CEO to BioStock: "Aiming for an agreement"	AQ
23/08/24	WntResearch Q2 - An eventful half-year ahead	AQ
28/06/24	WntResearch : Foxy-5 Poster ESMO GI 2024 WntResearch \|juni 2024	PU
20/06/24	WntResearch: WntResearch presents ad hoc observations from the NeoFox study at ESMO GI	PU
20/06/24	WntResearch presents ad hoc observations from the NeoFox study at ESMO GI	AQ
13/06/24	Redeye Initiates Coverage of WntResearch	AQ
27/05/24	WntResearch : Presentationen från AGM.	PU
08/05/24	WntResearch's CEO to BioStock: "If the effect is confirmed, there are good opportunities for licensing agreements next year"	AQ
02/04/24	BioStock: WntResearch's new CEO comments on his first month in the position	AQ
01/03/24	Resigning WntResearch CEO tells BioStock: "It will be exciting to follow!"	AQ
26/02/24	WntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea	AQ
12/02/24	WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5	AQ
08/02/24	WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8	AQ
07/02/24	WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue	AQ
31/01/24	WntResearch publishes outcome in rights issue	AQ
24/01/24	WntResearch's co-founder applies for subscription of additional units in the ongoing rights issue with a last day for subscription on 29 January 2024	AQ
08/01/24	WntResearch publishes prospectus in connection with rights issue	AQ
22/12/23	Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023	AQ
06/12/23	WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5	AQ
21/11/23	WntResearch's CEO: "In a better position than ever"	AQ